No Data
No Data
Analysts Offer Insights on Healthcare Companies: Moderna (MRNA), Argenx Se (ARGX) and NovoCure (NVCR)
ArGEN-X Is Maintained at Buy by HC Wainwright & Co.
ArGEN-X Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Argenx, Maintains $451 Price Target
HC Wainwright & Co. analyst Douglas Tsao maintains argenx with a Buy and maintains $451 price target.
Buy Rating Affirmed for Argenx Se on Strong Pipeline and Market Potential
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ascom Holding AG (OtherACMLF), Siemens Healthineers AG (OtherSEMHF) and Argenx Se (ARGX)
Argenx Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease
argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its plan to continue the development of efgartigimod to Phase 3 in adults with primary Sjogren's disease (SjD), following the analysis of topline data from the Phase 2 RHO study.
No Data